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TRAMP, a Novel Apoptosis-Mediating Receptor
with Sequence Homology to Tumor Necrosis Factor
Receptor 1 and Fas(Apo-1/CD95)
Jean-Luc Bodmer,*# Kim Burns,*# The receptor members of this family are type I mem-
brane molecules and are structurally homologous: eachPascal Schneider,*# Kay Hofmann,‡#
Ve´ronique Steiner,*# Margot Thome,*# contains in its extracellular domain three to six imperfect
repeats of approximately 40 residues, each containingThierry Bornand,* Michael Hahne,* Michael Schro¨ter,*
Karin Becker,* Anne Wilson,† Lars E. French,§ approximately six cysteines (Ware et al., 1996). A single
domain is formed by six b-sheets in which the cysteinesJeffrey L. Browning,‖ H. Robson MacDonald,†
and Ju¨rg Tschopp*§ are arranged in a typical 1-3, 2-4, 5-6 pattern (Banner
et al., 1993). The cytoplasmic domains generally lack*Institute of Biochemistry
†Ludwig Institute of Cancer Research sequence homology, with the exception of a motif called
the “death domain” found in TNFR1 and Fas (FeinsteinLausanne Branch
University of Lausanne et al., 1995; Hofmann and Tschopp, 1995; Tartaglia et al.,
1993b; Watanabe et al., 1992a). Both of these receptors‡Swiss Institute for Experimental Cancer Research
BIL Research Center efficiently transmit death signals, initiated through asso-
ciation of TNFR1-associated death domain proteinChemin des Boveresses 155
CH-1066 Epalinges (TRADD) and Fas-associating protein with death domain
(FADD) (Boldin et al., 1995b; Chinnaiyan et al., 1995),Switzerland
§Department of Dermatology respectively, which connect the receptors to interleukin-
1b-converting enzyme (ICE)-like cysteine proteases viaUniversity of Geneva Medical School
CH-1211 Geneva 4 FLICE/MACH (Boldin et al., 1996; Muzio et al., 1996).
The aspartate-specific proteases are implicated as me-Switzerland
‖Biogen, Inc. diators of most types of apoptotic cell death (Dixit, 1996;
Henkart, 1996; Kumar, 1995).Department of Immunology and Inflammation
14 Cambridge Center The ligand members are type II membrane molecules.
Their extracellular domains have b jelly-roll topographyCambridge, Massachusetts 02142
(Banner et al., 1993) and are important in ligand trimeri-
zation. Intrinsic to oligomerization is the formation of
the receptor-binding site at the junction between neigh-Summary
boring subunits creating a multivalent ligand. The bind-
ing of the ligands to their respective receptors inducesA novel member of the tumor necrosis factor (TNF)
oligomerization initiating downstream signaling events.receptor family, designated TRAMP, has been identi-
Except for the recently described ligand TRAIL (forfied. The structural organization of the 393 amino acid
TNF-related apoptosis-inducing ligand) (Pitti et al., 1996;long human TRAMP is most homologous to TNF re-
Wiley et al., 1995), receptors have been identified for allceptor 1. TRAMP is abundantly expressed on thymo-
members of the TNF ligand family (Smith et al., 1994).cytes and lymphocytes. Its extracellular domain is
Similar to Fas ligand (FasL), recombinant TRAIL cancomposed of four cysteine-rich domains,and thecyto-
induce cell death in a broad range of cells (Wiley et al.,plasmic region contains a death domain known to sig-
1995), suggesting that the structure of the correspond-nal apoptosis. Overexpression of TRAMP leads to two
ing receptor may show sequence homology to receptorsmajor responses, NF-kB activation and apoptosis.
known to induce apoptosis, i.e., Fas and TNFR1. There-TRAMP-induced cell death is inhibited by an inhibitor
fore, we have screened public databases for the pres-of ICE-like proteases, but not by Bcl-2. In addition,
ence of such a molecule and report here the character-TRAMP does not appear to interact with any of the
ization of a novel receptor displaying highest sequenceknown apoptosis-inducing ligands of the TNF family.
homology with TNFR1. We show that this receptor,
coined TRAMP, can elicit biological activities similar to
Introduction those described for TNFR1 (Tartaglia et al., 1993a), rang-
ing from activation of transcription factors to the induc-
The tumor necrosis factor (TNF)-related cytokines have tion of cell death. However, TRAMP does not appear to
emerged over recent years as a large family of pleiotro- be the cognate receptor of TRAIL or any member of the
pic mediators of host defense and immune regulation TNF ligand family known to trigger cell death.
(Smith et al., 1994). A parallel family of receptors medi-
ates the initiation of, among other things, cell death,
Resultsproliferation, anti-viral activities, and differentiation
(Smith et al., 1994; Ware et al., 1996). In mammals, ten
Identification of TRAMPreceptors have been identified, NGFR, TNF receptor 1
We reasoned that the receptor interacting with TRAIL(TNFR1), TNFR2, LTbR, CD40, CD30, CD27, 4-1BB, OX
most likely contains the typical TNF receptor cysteine-40, and Fas/Apo-1(CD95), which can interact with some
rich domain and searched the dbEST database usingeight TNF-related ligands.
an improved profile search (Bucher et al., 1996) based
on an optimal alignment of all family members. Five
candidate cDNA clones were found, four expressed in# These authors contributed equally to this work.
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Figure 1. Predicted Amino Acid Sequence of TRAMP and Its Homology to Fas and TNFR1
Colinear amino acid sequence alignment of human TRAMP, TNFR1, and Fas. Sequence numbering starts at the N-terminus of the predicted
mature protein. The cysteine-rich domains (I–IV), the predicted transmembrane segment (TM), and the death domain (DD) are indicated. The
C-terminus of the alternatively spliced form giving rise to the soluble form of TRAMP is marked with an arrow (stop). In the four clones coding
for the short version of TRAMP, the leucine was replaced by a proline at position 143. Identical and similar residues are represented in closed
and shaded boxes, respectively.
a brain cDNA library and one in a fetal lung cDNA library. the transcript size heterogeneity was considerable as
four prominent cross-hybridizing mRNAs were detect-Sequence analysis revealed that the 59-end sequences
of the clones were identical. The four shorter clones able migrating at approximately 1.0, 1.6, 3.4, and 4.5 kb.
The 1.0 kb was the major transcript detected in stromalpredicted a soluble receptor that consisted of three and
a half cysteine repeat units with a stop codon after cells of the spleen. Purified splenocytes, however, ex-
pressed mostly the1.6 kb and 4.8 kb message. In thymo-157 amino acids, with no indication of a hydrophobic
transmembrane region (Figure 1). In contrast, the longer cytes, the larger transcript(s) was most abundantly
expressed. Interestingly, the 1.0 kb message was selec-clone (1.7 kb) contained an open reading frame capable
of coding a sequence of 393 amino acids for the mature tively up-regulated in Fas-deficient lpr mice.
protein, preceded by hydrophobic amino acids typical
of a signal peptide. The predicted extracellular domain Characterization of the TRAMP Protein
In agreement with the Northern blot analysis, highestincluded four complete TNFR folds, followed by a puta-
tive transmembrane segment and a 193 amino acid long levels of the TRAMP protein were found in activated T
lymphocytes. Polyclonal antibodies generated againstcytoplasmic domain. Moreover, a region with homology
to the death domain previously found to be important the N-terminal sequence of TRAMP reacted with a pro-
tein of approximately 56 kDa, in agreement with the sizein signaling cell death (Itoh and Nagata, 1993; Tartaglia
et al., 1993b) was detected close to the C-terminus. of recombinant TRAMP overexpressed in 293T cells,
present in various human cell lines of epithelial, neu-The overall sequence of this novel receptor, which we
designate TRAMP (for TNF receptor–related apoptosis- ronal, and lymphocytic origin (Figure 3). Similar to the
related Fas and TNF receptors, TRAMP is most likelymediating protein) is most similar to TNFR1 (22.5% iden-
tical residues), followed by Fas (14%; Figure 1). Highest glycosylated, as the predicted molecular mass is 42.9
kDa. Differences in glycosylation may also explain thesequence similarity was found in the region of the death
domain, in which 40% of the residues are identical be- variations and heterogeneity of the molecular size among
different cells. In peripheral blood lymphocytes (PBLs), fortween TRAMP and TNFR1.
example, bands of 56 and 53 kDa were seen, while in
melanoma cell lines and U937, proteins of 56 and 59 kDaExpression of TRAMP
The expression of TRAMP was studied by Northern blot were detectable, respectively. It is noteworthy that TRAMP
expression in PBLs declined after prolonged stimulationanalysis (Figure 2A). A transcript of 3.2 kb was detected
in lymphocyte-rich tissues such as the thymus, colon, with the lectin PHA and interleukin-2.
intestine, and spleen. TRAMP mRNA was also found in
the prostate, whereas other tissues tested were neg- TRAMP Activates NF-kB
An important response induced by TNFR1 is the activa-ative.
TRAMP expression within lymphoid organs was stud- tion of the transcription factor NF-kB. This activity is
initiated by the oligomerization of the death domain ofied in more detail in mice (Figure 2B). In bone marrow,
TRAMP, an Apoptosis-Signaling Receptor
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Figure 4. Transcription Factor NF-kB Is Activated by TRAMP
Effect of increasing TRAMP expression on NF-kB activity in 293T
cells, determined by a TNF promoter–derived NF-kB–luciferasegene
reporter assay.
TRAMP Signals Apoptosis
The second signaling pathway triggered by the death
domain of TNFR1 (and Fas) is that leading to apoptosis.
To investigate a possible role of TRAMP in apoptosis, we
Figure 2. TRAMP Is Expressed in Lymphocyte-Rich Tissues transiently overexpressed TRAMP in 293T cells. Most
(A) Northern blot analysis of poly(A)1 RNA (2 mg per lane) of various of the transfected cells abundantly expressed TRAMP
human tissues.
(Figure 5A). When their morphology was examined by(B) Northern blot analysis of mouse bone marrow, splenocytes, and
phase-contrast microscopy 24 hr after transfection,remaining splenic stromal cells after splenocyte removal (left panel).
cells had rounded up and had undergone morphologicalThe right panel shows TRAMP transcripts in thymocytes from wild-
type and Fas-deficient lpr/lpr mutant mice. Blots were analyzed changes typical of apoptosis (Figure 5B). In contrast,
using a probe corresponding to the extracellular region of human cells transfected with an empty control vector retained
TRAMP. their flat adherent appearance. Inhibitors of ICE-like pro-
teases such as crmA encoded by the cowpox virus or
synthetic peptides can block TNF and FasL-induced
TNFR1 upon ligand binding, resulting in the binding of apoptosis (Los et al.,1995; Tewari and Dixit, 1995). When
the death domain of TRADD. To investigate a possible 293T cells were transiently transfected with TRAMP in
activation of the signaling pathway leading to NF-kB the presence of zVAD-fmk, an inhibitor of ICE-like prote-
activation, we transiently transfected 293T cells with a ases, cells retained their viable appearance. In contrast,
TNF promoter–derived NF-kB–luciferase reporter gene cotransfection of the bcl-2 cDNA (Borner et al., 1994)
and increasing amounts of the TRAMP expression vec- with the TRAMP expression plasmid did not rescue cells
tor. TRAMP expression strongly induced the activity of from death.
the reporter gene in a dose-dependent fashion (Figure A biochemical hallmark of apoptosis is the degrada-
4). In the presence of an inhibitor of apoptosis (see tion of nuclear DNA into oligonucleosome-sized frag-
below), an increase in luciferase activity of up to 25-fold ments (Peitsch et al., 1993; Russell, 1983), and indeed
TRAMP-expressing cells had fragmented nuclear DNAwas measured.
Figure 3. TRAMP Protein Expression in Vari-
ous Human Cell Lines
Western blot analysis of membrane fractions
of various human cells. SH-T58 (SK-N-SH),
neuroblastoma; G215 (LN215), glioblastoma;
PBLs activated with PHA and interleukin-2
for 48 hr and 120 hr, respectively; ME 260,
melanoma; HeLa, cervix cell line; SK-Me123,
melanoma; HT-29, colon carcinoma; LAN-1,
neuroblastoma; U937, monocytic cell line;
PBL, HEK293, embryonic kidney cell line,Jur-
kat, T cell leukemia; Raji, B cell lymphoma;
LG-2, Epstein–Barr virus–transformed B cell. Controls (right) were as follows: TRAMP cDNA, human Fas cDNA, and the empty vector (mock)
were transfected into 293T cells and cell extracts were assayed using the affinity-purified polyclonal antibody against TRAMP (AL104). The
quality of the anti-TRAMP antibody was also assayed on TRAMP–Fc and human Fas–Fc, respectively (Rec–Fc; 1 mg per lane).
Immunity
82
Figure 5. Apoptosis Induced by TRAMP Overexpression in 293T Cells Is Blocked by an Inhibitor of ICE-like Proteases
(A) Expression of TRAMP in 293T cells 12 hr after transient transfection of TRAMP cDNA in the presence of zVAD-fmk (a broad spectrum
inhibitor of ICE-like proteases). The smaller panel shows cells transfected with an empty control vector. The bar is 20 mm.
(B) Morphology of 293T cells transiently overexpressing TRAMP. Cells were transfected with the indicated expression vectors in the presence
or absence of zVAD-fmk and analyzed 24 hr later by phase-contrast microscopy. Bar is 50 mm.
(C) DNA fragmentation of TRAMP-transfected cells (see [B]) was analyzed by the determination of cytoplasmic histone-containing DNA
complexes.
(Figure 5C). Taken together, these results are consistent 1995). To this end, two expression vectors, both coding
for the identical cytoplasmic region of TRAMP but car-with the interpretation that TRAMP-induced apoptosis
involves the activation of ICE-like proteases, leading to rying two distinct tag epitopes (Myc and Flag) were
cotransfected into 293T cells. Figure 6B shows thatthe morphological and biochemical changes typical of
apoptosis. TRAMP forms homo-aggregates, whereas interaction
with the cytoplasmic region of Fas was not detectable.
The Death Domain of TRAMP Homo-Oligomerizes
and Can Recruit FADD TRAMP Does Not Appear to Be the Receptor
of TRAIL, TNFa, LTa1b2, or FasLThe downstream effector molecules that induce Fas-
mediated apoptosis are FADD and FLICE (for FADD-like To determine whether TRAMP is the receptor of one of
the known ligands of the TNF family, the extracellularICE) (Boldin et al., 1996; Muzio et al., 1996). FADD is a
typical linker protein with a N-terminal death domain domain of TRAMP was fused to the Fc portion of human
immunoglobulin G1 (IgG1) (TRAMP–Fc). The forced di-binding to the death domain of oligomerized Fas and a
C-terminal death effector domain interacting with the merization of the extracellular region of TNFR-like recep-
tors was previously shown to result in a considerabledeath effector domain of FLICE. The C-terminus of
FLICE, in turn, contains an ICE-like cysteine protease increase of affinity for the respective ligands such that
ligand–receptor interactions of the TNF family memberscoupling FAS to the ICE proteases. This led us to exam-
ine whether FADD can associate with TRAMP. The Flag- can be studied in vitro (Byrn et al., 1990). The TRAMP–Fc
and, for comparison, the Fc hybrids of human andtagged cytoplasmic domain of TRAMP (amino acids
197–393) was cotransfected with a FADD expression mouse Fas (mFas and hFas) (Itoh et al., 1991; Watanabe
et al., 1992b), mouse lymphotoxin b receptor (mLTbR)vector in 293T cells. Immunoprecipitation of Flag–
TRAMP revealed that FADD associated with TRAMP (Browning et al., 1993, 1996), and human TNFR1
(hTNFR1) (Loetscher et al., 1990) were coated onto wells(Figure 6A). Compared with parallel experiments using
the Flag-tagged cytoplasmic region of Fas and FADD, of microtiter plates, and an assortment of the soluble
version (without membrane anchor) of TNF ligand familyhowever, the interaction of TRAMP with FADD appeared
to be less efficient (data not shown) and was detectable members was added to test for possible binding. As
expected, strong interaction was found between hTNFaonly at very high FADD expression levels. These data
suggest that the cytoplasmic domain of TRAMP can and mTNFR1–Fc, hFasL and human or mouse Fas–Fc,
and hLTa1b2 and mLTbR–Fc (Figure 7A). In contrast,recruit FADD. It remains to be determined, however,
whether TRAMP directly associates with FADD or TRAMP–Fc did not show affinity for any ligand, including
the orphan ligand TRAIL. Since anti-TRAMP antibodieswhether TRAMP–FADD complex formation is mediated
by (endogenous) TRADD, as seen for TNFR1. recognized the TRAMP–Fc hybrid, we excluded the pos-
sibility that coating of the wells with TRAMP–Fc wasTransfection of the expression vector coding for the
cytoplasmic region of TRAMP into 293T cells was also inefficient and responsible for the inability to detect a
binding partner. This set of experiments also revealedused to investigate a possible homo-aggregation of
TRAMP. The fact that TRAMP overexpression leads to that TRAIL had no detectable affinity for any of the other
receptor–Fc constructs tested.the initiation of cell death in the absence of the ligand
suggested that overexpression of TRAMP most likely Finally, the expression levels of TRAMP and TRAIL
receptors were compared in various cell lines. In mela-results in the oligomerization of the cytoplasmic region,
as aggregation of the death domain is thought to be the noma cell lines, expression of both TRAMP and TRAIL
receptors was comparably high, while no correlationcrucial trigger of the apoptotic signal pathway (Boldin
et al., 1995a; Krammer et al., 1994; Nagata and Golstein, was found in Jurkat T lymphomas (and various other
TRAMP, an Apoptosis-Signaling Receptor
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and ligands (4-1BB) of the TNF family have been
mapped, indicating that these genes are clustered. An-
other gene cluster of TNF family members is found on
chromosome 12 (CD27R, 12p13; LTbR, 12p13; TNFR1,
12p13.2), whereas the genes coding for Fas, TNFR1,
and nerve growth factor receptor (NGFR) are distributed
on various other chromosomes (e.g., Fas, 10q24.1;
CD40R, 20q12; and NGFR, 17q21).
Discussion
We have characterized a novel member of the TNF re-
ceptor family, designated TRAMP. Like most members
of the TNF receptor family, the extracellular domain of
TRAMP contains repeats of cysteine-rich domains that
are known to be crucial for the interaction with its cog-
nate ligand. TRAMP is the fourth member of the TNF
receptor family (TNFR1, Fas, NGFR) that contains a
death domain in the cytoplasmic region. Its percentage
amino acid identity with the extracellular cysteine-rich
domain of TNFR1 and Fas is 29% and 24%, respectively
(for comparison, Fas and TNFR1 have 22% identical
amino acids). In the death domain, the sequence homol-
ogy between TRAMP and TNFR1 is highest (40%).
TRAMP expression is found predominantly in tissues
with a high content of lymphocytes. Of the cells and
cell lines tested, TRAMP was abundantly expressed on
activated lymphocytes and in thymocytes. Thus, TRAMP
Figure 6. Homo-Oligomerization of the Intracellular Region of
may be involved in the regulation of lymphocyte cellTRAMP and Its Interaction with FADD
number, the negative selection of thymocytes, or both.
(A) Interaction of TRAMP with FADD. 293T cells were transfected
Two distinct cDNAs were found that code for TRAMP.with Flag-tagged TRAMP (5 mg) and FADD (2 mg), and the FADD
One transcript includes a stop codon after the third ofexpression levels were assayed in cell lysates using a monoclonal
anti-FADD antibody. The cleared lysates were immunoprecipitated six cysteines of the fourth repeat, at a position where
with anti-Flag antibodies (precipitating TRAMP), and the presence the boundary between exons 5 and 6 is located in the
of coprecipitating FADD was assessed by Western blot analysis TNFR1 gene (Fuchs et al., 1992). Although there is cur-
using an anti-FADD antibody.
rently no evidence for the existence of such a soluble(B) Interaction of the intracellular regions of Flag-tagged TRAMP
protein, it would be predicted to act as a secreted inhibi-and Myc-tagged TRAMP upon overexpression in 293T cells. Levels
tor of TRAMP–TRAMP ligand interaction. Two otherof Myc–TRAMP and Myc–Fas expression in cell extracts were as-
sessed by Western blot analysis using an anti-Myc antibody (left). members of the TNF receptor family, both of poxvirus
Immunoprecipitates of cell extractsusing an anti-Flag antibody (pre- origin, also exist as soluble receptors. T2 and A53 func-
cipitating Flag–TRAMP) were analyzed by Western blot and revealed tion to complex host-produced TNF (Smith et al., 1991).
with an anti-Myc antibody to detect coprecipitating Myc–TRAMP
T2 is an acquired form of TNFR2, while A53 shows muchor Myc–Fas, respectively (right panel). It is noteworthy that TRAMP
lower sequence homology and may represent a thirdoligomers appeared to be extremely stable, since they were partially
TNF receptor. The fatal virulence of wild-type myxomaresistant to dissociation even in the presence of boiling SDS (see
bands .50 kDa). poxvirus is reduced by nearly 50% in viral mutants only
differing by an inactivated T2 gene (Upton et al., 1991).
It will thereforebe interesting to identify and characterize
the soluble TRAMP form. Interestingly, a short transcriptcell lines; data not shown), in which high TRAIL receptor
but only marginal TRAMP expression was detectable that possibly corresponds to the soluble receptor
TRAMP is highly up-regulated in mice that lack a func-(Figure 7B). Taken together, these results do not support
the possibility that TRAMP is the receptor of TRAIL. tional Fas.
The cytoplasmic region of TRAMP contains a death
domain, which has previously been shown to signal cellChromosomal Localization of TRAMP
The chromosomal localization of the TRAMP gene was death and NF-kB activation. Natural or artificial muta-
tions in this region disrupt the ability of Fas and TNFR1determined by fluorescence in situ hybridization (FISH)
analysis (Figure 8). Under the condition used, the hybrid- to initiate these signals (Nagata, 1994; Tartaglia et al.,
1993b). It was therefore not surprising that overexpres-ization efficiency of the TRAMP probe was approxi-
mately 91% (among 100 mitotic figures checked, 91 sion of TRAMP both potently induced proinflammatory
activity and cell death. Overexpression of TNFR1 hasshowed signals onone pairof the chromosome). TRAMP
was assigned to the long arm of human chromosome previously been shown to trigger NF-kB activation in a
ligand-independent manner (Smith et al., 1994). As1, region p36.2. Hence, the TRAMP gene is localized to
a region where other receptors (CD30R, TNFR2, OX40R) shown in Figure 6, overexpression of TRAMP resulted
Immunity
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Figure 7. TRAMP Does Not Appear to Be the Receptor of Known Apoptosis-Inducing Ligands of the TNF Family
(A) Interaction of TNF ligand and receptor family members. Wells of microtiter plates were coated with fusion proteins of the indicated TNF
receptor family members with human immunoglobulin Fc (rec–Fc). Binding of the tagged ligands was determined by the addition of anti-tag
antibodies (anti-Flag for for FasL, TRAIL, and TNFa; anti-Myc for LTa1b2). Efficient coating with TRAMP–Fc was verified using a polyclonal
anti-TRAMP antibody. In the control panel, no ligand was included in the assay.
(B) Comparison of TRAMP and TRAIL receptor surface expression. The distribution of TRAIL receptor and TRAMP (and for comparison Fas
and TNFRs) were compared in Me260 (Melanoma) and Jurkat (T cell lymphoma) cell lines. Surface expression of Fas, TNFRs, and TRAIL
receptor was analyzed by flow cytometry using tagged FasL, TNFa, and TRAIL, respectively. TRAMP expression was detected using the
polyclonal antibody AL104.
in aggregation of the cytoplasmic region, therefore Mch4 (Fernandesalnemri et al., 1996). TRAMP-triggered
cell death is blocked by zVAD-fmk, which is a potentallowing direct complex formation with downstream sig-
naling partners. Akin to TRADD-induced activation of inhibitor of ICE-like proteases, including FLICE (M. T.,
data not shown). In contrast, Bcl-2, a potent inhibitor ofNF-kB (Hsu et al., 1995), activation of the NF-kB reporter
gene was best demonstrated when the cell death path- other forms of signals causing apoptosis (UV, growth
factor withdrawal, etc.) (Hawkins and Vaux, 1994; Kors-way was inhibited, indicating that the cell death pathway
and the one leading to the proinflammatory response meyer, 1995) was ineffective, in agreement with its vari-
able inhibitory activity on the Fas pathway (Schroter etare distinct. Whether TRAMP-induced NF-kB activation
is mediated by TRADD remains to be determined. al., 1995; Strasser et al., 1995).
The possible interaction of TNF family membersTRAMP is also a potent inducer of cell death. Similar
to Fas, TRAMP is able to recruit FADD upon overexpres- known to induce cell death with TRAMP was assayed
using a sensitive enzyme-linked immunosorbent assay–sion, and it is reasonable to infer that TRAMP-com-
plexed FADD is able to bind FLICE or the FLICE homolog based assay. While strong signals were obtained with
TRAMP, an Apoptosis-Signaling Receptor
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Figure 8. Chromosomal Localization of the
TRAMP Gene
Diagram of FISH mapping results for the
TRAMP probe. Each dot represents the dou-
ble FISH signals detected on human chromo-
some 1p36.2. The left panel shows an exam-
ple of FISH mapping (arrowhead); the right
panel corresponds to the same mitotic figure
stained with DAPI.
Leu-233) were produced in bacteria (P. S., unpublished data). Myc-known ligands, no signal above background was mea-
tagged LTa1b2 was made in insect cells using the baculovirus sys-sured with TRAMP, suggesting that these members of
tem (Browning et al., 1996). Human and mouse Fas–Fc were purifiedthe TNF family, and in particular TRAIL, cannot bind
from supernatants of stably transfected 293 HEK cell lines; human
TRAMP. These results were supported by the fact that TRAMP–Fc was from transiently transfected 293T cell lines. Human
TRAIL receptor and TRAMP expression differed in vari- TNFR1–Fc and human LTbR–Fc were made as described previously
(Crowe et al., 1994). The FADD expression plasmid (pcDNA3) wasous cell lines tested. However, this conclusion has to
a gift of Dr. Martinou (Glaxo, Geneva).be taken with caution. The most conserved region, the
The extracellular domain of TRAMP, encompassing residuescytoplasmic death domain, is highly homologous to the
1–175, was amplified by PCR using the proofreading DNA polymer-corresponding region of TNFR1, and therefore the exis-
ase Pwo (Boehringer) using a specific 59 forward primer flanked by
tence of heterotrimeric receptors, consisting of, for ex- a BamHI site (59-TCCGGATCCCAGGGCGGCACTCGT-39) and a 39
ample, TNFR11TRAMP2, cannot be excluded. LTa1b2 reverse primer flanked by a SalI site (59-GTCGACCTGCCTCCAGCC
ACAG-39). The amplification product was cloned into the pCRII vec-may be considered the prototype of such a hetero-oligo-
tor (Invitrogen) and then subcloned in an expression vector con-mer in the TNF ligand family. If such a mixed receptor
taining the pCMV promoter (PCRIII; Invitrogen) as a BamHI–SalIassociation exists in vivo, the assay system used here
insert in-frame behind the signal sequence of the heavy chain ofwould have failed to detect it. Still, the most likely expla-
the immunoglobulin (Ig) and in front of a SalI–NotI fragment con-
nation is that the ligand of TRAMP is a novel member taining the cDNA of the hinge, CH3 and CH4 domains of the human
of the TNF ligand family, which, when identified, may IgG1 (Fc domain). This strategy resulted in the generation of a full-
length, highly expressed secreted TRAMP–Fc molecule.provide new insights into the pleiotropic biological activ-
Monoclonal antibodies (MAbs) used for immunoprecipitation andities of this family of ligands and receptors.
Western blotting include the following: an anti-Flag antibody and
anti-Flag agarose (Kodak International Biotechnologies), an anti-
FADD antibody directed against amino acids 94–208 of human FADDExperimental Procedures
(Transduction Laboratories), and an antibody against the Myc epi-
tope (9E10; provided by R. Iggo, ISREC). Antiserum against TRAMPReagents and Cell Lines
was generated against a peptide spanning amino acids 1–23 ofThe 293T human embryo kidney (HEK) cell line was a gift of Dr.
the mature TRAMP (QGGTRSPRCDCAGDFHKKIGLFC) synthesizedMarcus Peter (Heidelberg) and melanoma cell lines used have been
using the multiple antigen technology (Francis et al., 1991). Thedescribed previously (Hahne et al., 1996). Human peripheral blood
antiserum (AL104) was affinity purified on the TRAMP peptide cou-lymphocytes (PBLs) from a buffy coat preparation were purified
pled to CNBr-Sepharose 4B (Pharmacia).over Ficoll (Pharmacia). Cells were activated with 1 mg/ml PHA and
interleukin-2 (150 U/ml). LAN-1 and LN215 cells were a gift of Dr.
Nicole Gross and Dr. E. van Meir, respectively. Other cell lines re- Cloning of TRAMP cDNA
Several EST clones that potentially encoded a novel member of theferred to in this paper have been deposited in and described by the
American Type Culture Collection (Rockville, MD). All cell lines were TNF receptor family were identified in the dbEST database at the
National Center for Biotechnology Information by performing a data-cultured in RPMI medium supplemented with 10% fetal calf serum.
A Flag-tagged version of the extracellular domain (residues 103– base search using generalized profile method (Bucher et al., 1996)
based on the sequence homology among TNF receptor family mem-281) of human FasL was produced in 293 HEK cells (P. S., data not
shown). Flag-tagged recombinant soluble human TRAIL (residues bers. Four of the clones (insert size 0.6–0.8 kb) were derived from
an adult brain cDNA library (GenBank accession numbers H46378,Thr-95–Gly-281) and Flag-tagged human TNFa (residues Ser-85–
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H41851, H49675, and H41522); the longest clone (1.7 kb; GenBank AL104 antibody at 25 mg/ml, followed by anti-rabbit immunoglobu-
lin-FITC (Dianova, Hamburg, Federal Republic of Germany) dilutedaccession number N71141) was from a fetal lung cDNA library. The
inserts were sequenced by conventional methods, and the resulting 1:150 and examined by confocal microscopy (Zeiss).
sequences were aligned.
FACS Staining
Cells were stained with affinity-purified anti-TRAMP AL104 antibody
Northern Blot Analysis at a 1:20 dilution at 48C for 20 min, washed with fluorescence-
Northern blot analysis was performed by using human multiple tis- activated cell sorting (FACS) buffer (PBS, 10% FCS, 0.02% NaN3),sue Northern blots I and II (Clontech 7760-1 and 7759-1) or by pelleted at 200 3 g, and stained with anti-rabbit-FITC (Silenus Labo-
resolution of total RNA from mouse cells (Wilson et al., 1996) on ratory, Australia), diluted 1:400 for 20 min at 48C. Cells were washed
1.4% agarose gels containing 18% formaldehyde and blotting onto
and analyzed in the flow cytometer (Becton Dickinson).
Hybond-N membrane (Amersham). The membrane was preincu-
TRAIL receptor, Fas, and TNFR expression on cell lines was ana-
bated in hybridization solution (50% formamide, 2.53 Denhardt’s
lyzed by FACS using the respective Flag-tagged ligands (1 mg) as
solution, 0.2% SDS, 10 mM EDTA, 23 SSC [pH 7.0], 50 mM NaH2PO4 detecting probes. Bound ligands were detected with the anti-Flag
[pH 6.5], 200 mg/ml boiled and sonicated herring sperm DNA) for at
M2 antibody, followed by a FITC-labeled anti-mouse antibody (Di-
least 4 hr at hybridization temperature (608C). The heat-denatured
anova).
antisense RNA probe was added at 1.5 3 106 cpm per milliliter in
fresh hybridization solution. The membrane was incubated 12–24
NF-kB Reporter Assayhr at 658C andwashed at least three times with increasing stringency
Approximately 2 3 105 293T cells were seeded on 35 mm dishesand exposed at 2708C.
and grown in 5% CO2 at 378C. Cells were transfected the next day
by the calcium phosphate precipitation method. The precipitate was
removed after 8 hr, and the ICE family inhibitor zVAD-fmk (50 mM;Construction of TRAMP Expression Vectors
Enzyme Systems Products) was added. After 24 hr, cells wereThe full-length TRAMP was amplified using the Pwo DNA polymer-
washed twice with PBS and then lysed with 200 ml of Triton X-100,ase using a specific 59 forward primer flanked by a BamHI site
glycylglycine lysis buffer (1% Triton X-100, 25 mM glycylglycine [pH(59-TCCGGATCCCAGGGCGGCACTCGT-39) and a specific 39 re-
7.8], 14 mM MgSO4, 4 mM EGTA, 1 mM DTT). Aliquots of cell lysatesverse primer flanked by an XbaI site (59-GACTCTAGACGCCTAGGT
(1.5 ml) were mixed with 100 ml of luciferase assay reagent (Pro-GGCAAGT-39). The amplified fragment was cut with BamHI–XbaI
mega), and the luciferaseactivity was determined using a biocounterand cloned into a modified version of pCRIII (Invitrogen) in-frame
M2500 luminometer (Inotech, Zu¨rich). b-Galactosidase activity waswith the signal peptide of the heavy chain of IgG. The cytoplasmic
determined in a mixture containing 50 ml of cell extract and 50 mldomain of TRAMP (amino acids 197–393) was PCR amplified us-
of a buffer containing the substrate o-nitrophenyl-b-D-galactopyra-ing the two primers 59-GAATTCACCTACACATACCGC-39 and
noside (Sigma). Samples were incubated at 378C until a yellow color59-CTCGAGTCACGGGCCGCGCTG-39 containing an EcoRI and
developed and the absorbance was determined at 405 nm. TheseXhoI site, respectively, and subcloned into a modified pCRIII vector
values were used to normalize transfection efficiency.in-frame with an N-terminal Flag epitope.
Cell Death Assay
Cell Lysis, Coimmunoprecipitation, and Western Blot Analysis 293T cells (2 3 105) were transiently transfectedwith either theempty
For analysis of various cell lines for TRAMP expression, cells were vector (1 mg) or pcDNA3 expression construct encoding TRAMP (1
harvested and submitted twice to Triton X-114 extraction (Bordier,
mg), Bcl-2 (1 mg), or both. Expression was confirmed by Western
1981). The detergent phases were pooled, and proteins were precip- blot analysis on whole-cell extracts. The ICE family inhibitor zVAD-
itated by the addition of MeOH/CHCl3 (1:4 [v/v]). Protein concentra- fmk was added, where indicated, at a concentration of 50 mM 8 hr
tion was determined using the BCA protein determination kit after transfection. At 24 hr following transfection, the extent of cell
(Pierce). Membrane proteins (20 mg) were diluted in SDS sample death was assessed by the morphology of the cells. Nuclear DNA
buffer andanalyzed for TRAMP expression by SDS–PAGE and West- degradation was determined in lysed cells using a kit from Boeh-
ern blotting. For coimmunoprecipitation experiments, 293T cells ringer (Number 1544 675) that detects cytoplasmic histone-associ-
were transfected with 5 mg of each plasmid by the calcium phos- ated DNA fragments.
phate procedure (Sambrook et al., 1989) for 8 hr. At 26 hr after
transfection, cells from a 10 mm plate were lysed in 200 ml of lysis
Ligand Binding Assay
buffer (1% NP-40, 20 mM Tris–HCl [pH 7.4], 150 mM NaCl) supple-
Wells of microtiter plates were coated with various receptor–Fc
mented with 1 mM EGTA, 1 mM pefabloc-sc (Serva), and 10 mg/ml
constructs at 1 mg/ml in PBS (100 ml per well) overnight at room
of each leupeptin and aprotinin (Sigma). Postnuclear lysates were temperature. After blocking with PBS containing 5% fetal calf serum
precleared for at least 1 hr on Sepharose 6B (Pharmacia) before (FCS) for 1 hr at 378C, wells were washed four times with PBS
precipitation for 2 hr or overnight with 3 ml of anti-Flag agarose or containing 0.05% Tween 20. The various ligands were added at 1
1 mg of anti-Myc (9E10) previously bound to protein G–Sepharose
mg/ml in 100 ml of PBS containing 1 mg/ml BSA for 1.5 hr at 378C, and
(Pharmacia). Precipitates were washed twice with lysis buffer con- after four washes with PBS, 0.05% Tween 20, anti-tag antibodies (1
taining 1% NP-40, boiled in sample buffer, analyzed by SDS–PAGE,
mg/ml anti-Flag M2 for FasL, TRAIL, and TNF; anti-Myc 9E10 for
and transferred to nitrocellulose (Hybond ECL, Amersham). For LTa1b2) in PBS containing 5% FCS were added and incubated for
Western blot analysis of cell extracts and immunoprecipitates, blots
1 hr at 378C. After addition of anti-mouse peroxidase conjugates,
were blocked with 5% skim milk, 0.5% Tween 20 in PBS and re-
the peroxidase activity was revealed using H2O2 and o-phenylenedi-vealed using affinity-purified anti-TRAMP antibody AL104 at 1:2000
amine dihydrochloride (OPD; Sigma) as substrates. Binding of anti-
dilution, anti-Flag MAb at 5 mg/ml, anti-FADD MAb at 1 mg/ml, and
TRAMP antibodies (1 mg/ml) to receptor–Fc was detected with anti-
anti-Myc MAb (9E10) at 5 mg/ml, followed by incubation with per-
rabbit peroxidase conjugates.
oxidase-conjugated secondary antibody (Jackson Laboratories).
Bound antibody was detected using the enhanced chemilumines-
In Situ Hybridization and FISH Detectioncence kit (Amersham) according to the instructions of the manufac-
The biotinylated full-length cDNA of TRAMP was used in FISH analy-turer.
sis to probe normal human lymphocyte metaphases as described
previously (Heng and Tsui, 1993).
Immunofluorescence
293T cells plated onto coverslips at a density of 2 3 105 cells in a Acknowledgments
35 mm dish were transfected with 1 mg of full-length TRAMP con-
struct. At 20 hr after transfection, the coverslips were fixed in 4% Correspondence should be addressed to J. T. We thank Dr. Chris
Kamel for critical reading of this manuscript. This work was sup-formaldehyde in PBS, followed by a 10 min incubation in 95% EtOH,
5% acetic acid. Cells were stained with affinity-purified anti-TRAMP ported by grants of the Swiss National Science Foundation and the
TRAMP, an Apoptosis-Signaling Receptor
87
Human Frontier Science Program. and localization to chromosome 12p13. Genomics 13, 219–224. Er-
ratum: Genomics 13, 1384.
Hahne, M., Rimoldi, D., Schro¨ter, M., Romero, P., Schreier, M.,Received October 23, 1996; revised December 2, 1996.
French, L.E., Schneider, P., Bornand, T., Fontana, A., Lienard, D.,
Cerottini, J.-C., and Tschopp, J. (1996). Melanoma cells expressReferences
Fas(Apo-1/CD95) ligand: implications for tumor immune escape.
Science 274, 1363–1366.Banner, D.W., D’Arcy, A., Janes, W., Gentz, R., Schoenfeld, H.J.,
Hawkins, C.J., and Vaux, D.L. (1994). Analysis of the role of bcl-2Broger, C., Loetscher, H., and Lesslauer, W. (1993). Crystal structure
in apoptosis. Immunol. Rev. 142, 127–139.of the soluble human 55 kd TNF receptor-human TNFb complex:
implications for TNF receptor activation. Cell 73, 431–445. Heng, H., and Tsui, L. (1993). Modes of DAPI banding and simultane-
ous in situ hybridization. Chromosoma 102, 325–332.Boldin, M.P., Mett, I.L., Varfolomeev, E.E., Chumakov, I., Shemer-
avni, Y., Camonis, J.H., and Wallach, D. (1995a). Self-association of Henkart, P.A. (1996). ICE family proteases: mediators of all apoptotic
the death domains of the p55 tumor necrosis factor (TNF) receptor cell death? Immunity 4, 195–201.
and Fas/Apo1 prompts signaling for TNF and Fas/Apo1 effects. J. Hofmann, K., and Tschopp, J. (1995). The death domain motif found
Biol. Chem. 270, 387–391. in Fas (Apo-1) and TNF receptor is present in proteins involved in
Boldin, M.P., Varfolomeev, E.E., Pancer,C., Mett, I.L., Camonis, J.H., apoptosis and axonal guidance. FEBS Lett. 371, 321–323.
and Wallach, D. (1995b).A novel protein that interacts with the death Hsu, H., Xiong, J., and Goeddel, D.V. (1995). The TNF receptor
domain of Fas/Apo1 contains a sequence motif related to the death 1–associated protein TRADD signals cell death and NF-kB activa-
domain. J. Biol. Chem. 270, 7795–7798. tion. Cell 81, 495–504.
Boldin, M.P., Goncharov, T.M., Goltsev, Y.V., and Wallach, D. (1996). Itoh, N., and Nagata, S. (1993). A novel protein domain required for
Involvement of MACH, a novel MORT1/FADD-interacting protease, apoptosis: mutational analysis of human Fas antigen. J. Biol. Chem.
in Fas/APO-1- and TNF receptor–induced cell death. Cell 85, 268, 10932–10937.
803–815.
Itoh, N., Yonehara, S., Ishii, A., Yonehara, M., Mizushima, S.-I.,
Bordier, C. (1981). Phase separation of integral membrane proteins Sameshima, M., Hase, A., Seto, Y., and Nagata, S. (1991). The poly-
in Triton X-114 solution. J. Biol. Chem. 256, 1604–1607. peptide encoded by the cDNA for human cell surface antigen Fas
can mediate apoptosis. Cell 66, 233–243.Borner, C., Martinou, I., Mattmann, C., Irmler, M., Schaerer, E., Mar-
tinou, J.C., and Tschopp, J. (1994). The protein bcl-2 a does not Korsmeyer, S.J. (1995). Regulators of cell death. Trends Genet. 11,
require membrane attachment, but two conserved domains to sup- 101–105.
press apoptosis. J. Cell Biol. 126, 1059–1068. Krammer, P.H., Dhein, J., Walczak, H., Behrmann, I., Mariani, S.,
Browning, J.L., Ngam-ek, A., Lawton, P., DeMarinis, J., Tizard, R., Matiba, B., Fath, M., Daniel, P.T., Knipping, E., Westendorp, M.O.,
Chow, E.P., Hession, C., O’Brine-Greco, B., Foley, S.F., and Ware, et al. (1994). The role of APO-1-mediated apoptosis in the immune
C.F. (1993). Lymphotoxin b, a novel member of the TNF family that system. Immunol. Rev. 42, 175–191.
forms a heteromeric complex with lymphotoxin on the cell surface. Kumar, S. (1995). ICE-like proteases in apoptosis. Trends Biochem.
Cell 72, 847–856. Sci. 20, 198–202.
Browning, J.L., Miatkowski, K., Griffiths, D.A., Bourdon, P.R., Hes- Loetscher, H., Pan, Y.C., Lahm, H.W., Gentz, R., Brockhaus, M.,
sion, C., Ambrose, C.M., and Meier, W. (1996). Preparation and Tabuchi, H., andLesslauer, W. (1990). Molecular cloning and expres-
characterization of soluble recombinant heterotrimeric complexes sion of the human 55 kd tumor necrosis factor receptor. Cell 61,
of human lymphotoxins a and b. J. Biol. Chem. 271, 8618–8626. 351–359.
Bucher, P., Karplus, K., Moeri, N., and Hofmann, K. (1996). A flexible Los, M., Van de Craen, M., Penning, L.C., Schenk, H., Westendorp,
search technique based on generalized profiles. Comput. Chem. M., Baeuerle, P.A., Droge,W., Krammer, P.H., Fiers, W., and Schulze-
20, 3–24. Osthoff, K. (1995). Requirement of an ICE/CED-3 protease for Fas/
Byrn, R.A., Mordenti, J., Lucas, C., Smith, D., Marsters, S.A., John- APO-1-mediated apoptosis. Nature 375, 81–83.
son, J.S., Cossum, P., Chamow, S.M., Wurm, F.M., Gregory, T., et Muzio, M., Chinnaiyan, A.M., Kischkel, F.C., O’Rourke, K., Shev-
al. (1990). Biological properties of a CD4 immunoadhesin. Nature chenko, A., Ni, J., Scaffidi, C., Bretz, J.D., Zhang, M., Gentz, R.,
344, 667–670. Mann, M., Krammer, P.H., Peter, M.E., and Dixit, V.M. (1996). FLICE,
Chinnaiyan, A.M., Orourke, K., Tewari, M., and Dixit, V.M. (1995). a novel FADD-homologous ICE/CED-3-like protease, is recruited to
FADD, a novel death domain-containing protein, interacts with the the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 85,
death domain of Fas and initiates apoptosis. Cell 81, 505–512. 817–827.
Nagata, S. (1994). Mutations in the Fas antigen gene in lpr mice.Crowe, P.D., Van Arsdale, T.L., Walter, B.N., Ware, C.F., Hession,
Semin. Immunol. 6, 3–8.C., Ehrenfels, B., Browning, J.L., Din, W.S., Goodwin, R.G., and
Smith, C.A. (1994). A lymphotoxin-b-specific receptor. Science 264, Nagata, S., and Golstein, P. (1995). The Fas death factor. Science
707–710. 267, 1449–1456.
Dixit, V.M. (1996). The cell-death machine. Curr. Biol. 6, 555–562. Peitsch, M.C., Polzar, B., Stephan, H., Crompton, T., MacDonald,
H.R., Mannherz, H.G., and Tschopp, J. (1993). Characterization ofFeinstein, E., Kimchi, A., Wallach, D., Boldin, M., and Varfolomeev,
the endogenous deoxyribonuclease involved in nuclear DNA degra-E. (1995). The death domain: a module shared by proteins with
dation during apoptosis (programmed cell death). EMBO J. 12,diverse cellular functions. Trends Biochem. Sci. 20, 342–344.
371–377.Fernandesalnemri, T., Armstrong, R.C., Krebs, J., Srinivasula, S.M.,
Pitti, R.M., Marsters, S.A., Ruppert, S., Donahue, C.J., Moore, A.,Wang, L., Bullrich, F., Fritz, L.C., Trapani, J.A., Tomaselli, K.J., Lit-
and Ashkenazi, A. (1996). Induction of apoptosis by Apo-2 ligand,wack, G., and Alnemri, E.S. (1996). In vitro activation of CPP32
a new member of the tumor necrosis factor cytokine family. J. Biol.and Mch3 by Mch4, a novel human apoptotic cysteine protease
Chem. 271, 12687–12690.containing two FADD-like domains. Proc. Natl. Acad. Sci. USA 93,
7464–7469. Russell, J.H. (1983). Internal disintegration model of cytotoxic lym-
phocyte-induced target damage. Immunol. Rev. 72, 97–118.Francis, M.J., Hastings, G.Z., Brown, F., McDermed, J., Lu, Y.A., and
Tam, J.P. (1991). Immunological evaluation of the multiple antigen Sambrook, J., Fritsch, E.F., and Maniatis, T. (1989). Molecular Clon-
peptide (MAP) system using the major immunogenic site of foot- ing: A Laboratory Manual (Cold Spring Harbor, New York: Cold
and-mouth disease virus. Immunology 73, 249–254. Spring Harbor Laboratory Press).
Schroter, M., Lowin, B., Borner, C., and Tschopp, J. (1995). Regula-Fuchs, P., Strehl, S., Dworzak, M., Himmler, A., and Ambros, P.F.
(1992). Structure of the human TNF receptor 1 (p60) gene (TNFR1) tion of fas(apo-1/cd95)- and perforin-mediated lytic pathways of
Immunity
88
primary cytotoxic T lymphocytes by the protooncogene bcl-2. Eur.
J. Immunol. 25, 3509–3513.
Smith, C.A., Davis, T., Wignall, J.M., Din, W.S., Farrah, T., Upton,
C., McFadden, G., and Goodwin, R.G. (1991). T2 open reading frame
from the Shope fibroma virus encodes a soluble form of the TNF
receptor. Biochem. Biophys. Res. Commun. 176, 335–342.
Smith, C.A., Farrah, T., and Goodwin, R.G. (1994). The TNF receptor
superfamily of cellular and viral proteins: activation, costimulation,
and death. Cell 76, 959–962.
Strasser, A., Harris, A.W., Huang, D.C.S., Krammer, P.H., and Cory,
S. (1995). Bcl-2 and Fas/Apo-1 regulate distinct pathways to lym-
phocyte apoptosis. EMBO J. 14, 6136–6147.
Tartaglia, L.A., Rothe, M., Hu, Y.F., and Goeddel, D.V. (1993a). Tumor
necrosis factor’s cytotoxic activity is signaled by the p55 TNF recep-
tor. Cell 73, 213–216.
Tartaglia, L.A., Ayres, T.M., Wong, G.H., and Goeddel, D.V. (1993b).
A novel domain within the 55 kd TNF receptor signals cell death.
Cell 74, 845–853.
Tewari, M., and Dixit, V.M. (1995). Fas- and tumor necrosis factor-
induced apoptosis is inhibited by the poxvirus CrmA gene product.
J. Biol. Chem. 270, 3255–3260.
Upton, C., Macen, J.L., Schreiber, M., and McFadden, G. (1991).
Myxoma virus expresses a secreted protein with homology to the
tumor necrosis factor receptor gene family that contributes to viral
virulence. Virology 184, 370–382.
Ware, C.F., Vanarsdale, S., and Vanarsdale, T.L. (1996). Apoptosis
mediated by the TNF-related cytokine and receptor families. J. Cell.
Biochem. 60, 47–55.
Watanabe, F.R., Brannan, C.I., Copeland, N.G., Jenkins, N.A., and
Nagata, S. (1992a). Lymphoproliferation disorder in mice explained
by defect in Fas antigen that mediates apoptosis. Nature 356,
314–317.
Watanabe, F.R., Brannan, C.I., Itoh, N., Yonehara, S., Copeland,
N.G., Jenkins, N.A., and Nagata, S. (1992b). The cDNA structure,
expression, and chromosomal assignment of the mouse Fas anti-
gen. J. Immunol. 148, 1274–1279.
Wiley, S.R., Schooley, K., Smolak, P.J., Din, W.S., Huang, C.P., Ni-
choll, J.K., Sutherland, G.R., Smith, T.D., Rauch, C., Smith, C.A.,
and Goodwin, R.G. (1995). Identification and characterization of a
new member of the TNF family that induces apoptosis. Immunity 3,
673–682.
Wilson, A., de Villartay, J.P., and MacDonald, H.R. (1996). T cell
receptor d gene rearrangement and T early a (TEA) expression in
immature ab lineage thymocytes: implications for ab/gd lineage
commitment. Immunity 4, 37–45.
GenBank Accession Numbers
The accession numbers for the two TRAMP cDNA sequences re-
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